论文信息 - Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM‐3 antibody, in combination with decitabine or azacitidine in high‐ or very high‐risk myelodysplastic syndromes - 字舞流文

Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM‐3 antibody, in combination with decitabine or azacitidine in high‐ or very high‐risk myelodysplastic syndromes

G. Garcia-Manero | D. Steensma | U. Borate | E. Traer | K. Porkka | M. Wermke | M. Kontro | Anisa Mohammed | N. Tovar | Haiying Sun | Rupa Narayan | C. Sabatos-Peyton | S. Loo | P. Naidu | Mikael L Rinne | Sebastian Scholl | Norbert Vey | Oliver G. Ottmann | Andrew M Brunner | S. Knapper | Andrew H. Wei | Jordi Esteve | J. J. W. M. Janssen | Shaun Fleming | May Han | Roisin White | Na Zhang